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OBJECTIVES This study aimed to examine: 1) whether nicorandil protects the ischemic myocardium by
activating sarcolemmal adenosine triphosphate (ATP)-sensitive K (sarcKATP) channels or
the mitochondrial KATP (mitoKATP) channels, and 2) whether protein kinase C (PKC)
activity is necessary for cardioprotection afforded by nicorandil.
BACKGROUND Nicorandil is a hybrid of nitrate and a KATP channel opener that activates the sarcKATP and
mitoKATP channels. Both of these KATP channels are regulated by PKC, and this kinase may
be activated by nitric oxide and also by oxygen free radicals (OFR) generated after mitoKATP
channel opening.
METHODS In isolated rabbit hearts, infarction was induced by 30-min global ischemia/2-h reperfusion
with monitoring of the activation recovery interval (ARI), an index of action potential
duration. Protein kinase C translocation was assessed by Western blotting.
RESULTS Nicorandil did not change ARI before ischemia, but it accelerated ARI shortening after the
onset of ischemia and reduced infarct size by 90%. A sarcKATP channel selective blocker,
HMR1098, abolished acceleration of ischemia-induced ARI-shortening by nicorandil and
eliminated 40% of nicorandil-induced infarct size limitation. A mitoKATP channel selective
blocker, 5-hydroxydecanoate, abolished the protection afforded by nicorandil without
affecting ARI. Cardioprotection by nicorandil was inhibited neither by an OFR scavenger,
N-2-mercaptopropionylglycine nor by a PKC inhibitor, calphostin C, at a dose that was
capable of inhibiting PKC- translocation after preconditioning.
CONCLUSIONS Both the sarcKATP and mitoKATP channels are involved in anti-infarct tolerance afforded by
nicorandil, but PKC activation induced by nitric oxide or OFR generation, if any, does not
play a crucial role. (J Am Coll Cardiol 2002;40:1523–30) © 2002 by the American College
of Cardiology Foundation
Nicorandil is currently the only adenosine triphosphate
(ATP)-sensitive K (KATP) channel opener that is used for
patients with coronary artery disease. Cardioprotective ef-
fects of KATP channel openers, including nicorandil, have
been demonstrated in various animal models of myocardial
ischemia/reperfusion (1–4). Furthermore, clinical studies
(5–8) have shown that nicorandil infusion attenuates elec-
trocardiographic changes during coronary occlusion and
that this agent improves functional recovery of the reper-
fused myocardium in patients with acute myocardial infarc-
tion. Most recently, the Impact Of Nicorandil in Angina
(IONA) study, which was a double-blind placebo-
controlled trial in which more than 5,000 patients were
recruited, demonstrated that nicorandil improves the prog-
nosis of stable angina pectoris (9). However, the molecular
mechanisms of these beneficial effects of nicorandil remain
unclear.
Because nicorandil is a hybrid agent with KATP channel
opener and nitrate properties (10,11), it can activate the
sarcolemmal KATP (sarcKATP) and mitochondrial KATP
(mitoKATP) channels and also release nitric oxide (NO).
Furthermore, there may be some interaction between these
mechanisms to protect ischemic cardiomyocytes. First, it is
possible that NO released from nicorandil activates the
mitoKATP channels (12). Second, protein kinase C (PKC)
may mediate cardioprotection triggered by both NO and
the mitoKATP channels. A recent study by Nakano et al.
(13) showed that anti-infarct tolerance of the myocar-
dium afforded by a NO donor, S-nitroso-N-acetyl-DL-
penicillamine (SNAP), was abolished by a PKC inhibitor,
chelerythrine. It has also been suggested that opening of the
mitoKATP channel induces a burst of free radicals from the
mitochondria and, thus, activates PKC (14,15). On the
other hand, it has been known for some time that PKC
regulates the activity of sarcKATP (16) and mitoKATP
channels (17). Taken together, the findings suggest that
cardioprotection by nicorandil may not be simply due to
opening of sarcKATP or mitoKATP channels but may involve
a complex interaction among these KATP channel subtypes,
NO and PKC.
In the present study, we used a novel sarcKATP channel
selective blocker, HMR1098 (18,19), and a mitoKATP
channel blocker, 5-hydroxydecanoate (5-HD), to differen-
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tiate the contribution of each KATP channel subtype to
cardioprotection by nicorandil. The role of NO derived
from nicorandil could not be directly examined because no
selective agent is available for inhibiting the mechanism of
NO release from nicorandil (20,21). However, contribu-
tions of PKC and free radicals to the nicorandil-induced
cardioprotection were assessed by using calphostin C, a
PKC inhibitor, and N-2-mercaptopropionylglycine
(MPG), a free radical scavenger. Effects of pharmacologic
agents on the sarcKATP channel were monitored by mea-
suring the activation recovery interval (ARI), an index of
action potential duration. Efficacy of calphostin C was
confirmed by its effect on PKC translocation by ischemic
preconditioning, which has been shown to afford PKC-
mediated anti-infarct tolerance (22,23).
METHODS
This study was conducted in accordance with the Guide for
the Care and Use of Laboratory Animals published by the
U.S. National Institute of Health (NIH publication No.
85-23, revised 1996) and was approved by the Animal Use
Committee of Sapporo Medical University.
Experiment 1: effects of KATP channel blockers, calphos-
tin C and MPG, on infarct size-limiting effects of
nicorandil. PREPARATION. Isolated rabbit hearts were pre-
pared as previously described (24,25). In brief, hearts were
excised from male albino rabbits (Japanese White) that had
been anesthetized and mechanically ventilated. Each excised
heart was quickly mounted on a Langendorff apparatus with
a water jacket and perfused at a pressure of 75 mm Hg with
a noncirculating modified Krebs-Henseleit buffer at 38°C
(NaCl, 118.5 mM; KCl, 4.7 mM; MgSO4, 1.2 mM;
KH2PO4, 1.2 mM; NaHCO3, 24.8 mM; CaCl2, 2.5 mM;
and glucose, 10 mM), which was continuously oxygenated
by 95% O2 and 5% CO2. A fluid-filled latex balloon
connected to a transducer (Nihon-Kohden, Tokyo, Japan)
with PE-160 tubing was inserted into the left ventricle via
the left atrium to monitor ventricular pressure, and the
balloon volume was adjusted to maintain baseline end-
diastolic pressure within 0 to approximately 5 mm Hg. A
unipolar electrode was attached to the surface of the left
ventricle by using an elastic net, and an epicardial electro-
cardiogram and its electronically obtained first derivatives
were continuously recorded. The ARI was determined as
the interval between the times of minimum derivative of the
QRS and maximum derivative of the T-wave (26,27). Right
atrial pacing was performed at 200 beats/min when the
spontaneous rate was lower. Coronary flow was measured by
collection of perfusate in a graduated cylinder. The heart
was excluded from the study if the left ventricular systolic
pressure was below 70 mm Hg after a 20-min stabilization
period.
Experimental protocols. PROTOCOL 1. After a 20-min
stabilization period, each heart was subjected to 30-min
global ischemia and 2-h reperfusion. Before global ischemia,
hearts were untreated or received nicorandil (100 M) with
or without 100 M 5-HD, or 5 M HMR1098. Nicoran-
dil was infused for 10 min before the onset of ischemia.
Infusion of the KATP channel blockers was started 5 min
before the onset of nicorandil administration and continued
for 15 min.
PROTOCOL 2. Hearts were untreated or received nicorandil
with or without 200 nM calphostin C or 300 M MPG
before 30-min global ischemia/2-h reperfusion. Nicorandil
was administered for 10 min as in protocol 1, and calphostin
C and MPG were infused for 15 min before ischemia. In
this protocol, ARI was not determined.
Determination of infarct size. After 2 h of reperfusion,
the heart was removed from the Langendorff apparatus,
weighed, frozen, and cut into 2-mm-thick sections from
apex to base. The uppermost slice containing the valves was
not used for infarct size determination. The heart slices were
incubated in 1% solution of triphenyltetrazolium chloride in
100 mM sodium phosphate buffer (pH 7.4) for 15 min at
37°C. Each slice was traced on a clear acetate sheet, and the
traces were read by a Macintosh G3 computer using a
Hewlett Packard ScanJetIIC scanner (Hewlett Packard,
Palo Alto, California). The area of infarct and the left
ventricle (i.e., area at risk) in each slice were measured using
NIH Image, an image analysis program, and multiplied by
the thickness of the heart slice to obtain their volumes.
Experiment 2: effects of calphostin C on PKC translo-
cation by ischemic preconditioning. PREPARATION AND
EXPERIMENTAL PROTOCOL. This series of experiments was
performed to confirm that 200 nM calphostin C, which is
well above the reported IC50 of this PKC inhibitor (i.e., 50
nM), is sufficient to inhibit PKC in rabbit hearts in
experiment 1. Because PKC- and PKC- are cardiopro-
tective isoforms in the rabbit and rat, respectively (28–30),
we assessed the effects of calphostin C on these PKC
isoforms. Rabbit hearts were perfused as in experiment 1
Abbreviations and Acronyms
ARI  activation recovery interval
KATP channel  adenosine triphosphate-sensitive
K channel
LVEDP  left ventricular end-diastolic
pressure
LVDP  left ventricular developed pressure
mitoKATP channel  mitochondrial adenosine
triphosphate-sensitive K channel
MPG  N-2-mercaptopropionylglycine
NO  nitric oxide
PC  ischemic preconditioning
PKC  protein kinase C
sarcKATP channel  sarcolemmal adenosine
triphosphate-sensitive K channel
SNAP  S-nitroso-N-acetyl-DL-penicillamine
SUR  sulfonylurea receptor
5-HD  5-hydroxydecanoate
%IS/LV  infarct size as a percentage of the
left ventricle
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and subjected to one of three treatments: PC with two
cycles of 5-min ischemia/5-min reperfusion, calphostin C
plus PC, and calphostin C infusion for 15 min. Calphostin
C infusion was started 5 min before PC in the group that
received combination of calphostin C and PC. In each study
group, left ventricular biopsy samples (0.5 to approximately
1.0 g) were taken from the hearts before and after treatment.
The tissues were frozen in liquid nitrogen and stored at
70°C until Western blotting according to the method
reported previously (31). In brief, frozen samples were
homogenized in cold buffer containing 50 mM Tris-HCl
(pH 7.4), 5 mM EDTA, 10 mM EGTA, 50 mM NaF, 50
g/ml phenylmethylsulfonyl fluoride, 10 g/ml leupeptin,
and 0.3% -mercaptoethanol. The supernatant after cen-
trifugation at 1,000 g for 10 min was recentrifuged at
100,000 g for 60 min. The 100,000 g supernatant was used
as a cytosolic fraction. Particulate fraction samples were
obtained by treating the 100,000 g pellet with 0.3% Triton
X-100 and recentrifugation at 10,000 g for 10 min. Protein
concentration was determined using a Bio-Rad Protein
Assay Kit (Bio-Rad, Hercules, California).
Western blotting of PKC. Samples of cytosolic and par-
ticulate fractions were electrophoresed on a 12.5% poly-
acrylamide gel and blotted onto polyvinylidene difluoride
membranes (Millipore Co., Bedford, Massachusetts). The
blots were blocked with 5% nonfat dry milk in buffer
containing 100 mM NaCl, 10 mM Tris-HCl (pH 7.4), and
0.1% Tween 20 for 1 h. The blots were then incubated with
1,000-fold-diluted antibody against PKC- or PKC- (Trans-
duction Laboratories, Lexington, Kentucky). Protein kinase C
was then visualized using an ECL detection kit (Amersham,
Little Chalfont, Minnesota) and quantified by using Sigma-
Gel, gel analysis software (SPSS Inc., Chicago, Illinois).
Chemicals. Nicorandil and HMR1098 were kindly pro-
vided by Chugai Pharmaceutical Co. (Tokyo, Japan) and
Aventis Pharmaceuticals (Frankfurt, Germany), respec-
tively. Calphostin C and 5-HD were purchased from Sigma
(St. Louis, Missouri).
Statistics. All data are presented as means  SE. Hemo-
dynamic variables in study groups were compared by two-
way repeated measures analysis of variance. One-way anal-
ysis of variance with the Student Newman-Keuls post-hoc
test was used to test for differences in infarct size between
groups. The difference was considered significant if the p
value was 0.05.
RESULTS
Experiment 1. PROTOCOL 1. Hemodynamic parameters and
ARI. Of 44 hearts used in this series of experiments, two
hearts in the control group and one heart each in the
5-HD–treated groups were excluded according to the ex-
clusion criteria. Heart rate, left ventricular developed pres-
sure (LVDP), left ventricular end-diastolic pressure
(LVEDP), coronary flow (Table 1), and ARI (Fig. 1) were
comparable in study groups under baseline conditions. In
the untreated control group, ARI was significantly short-
ened during ischemia, indicating activation of the sarcKATP
channel, and LVDP after reperfusion was depressed by
approximately 70%. Before ischemia, nicorandil did not
modify heart rate, LVDP, or LVEDP but significantly
increased coronary flow by approximately 40%. Nicorandil
had no effect on ARI before the onset of ischemia but
significantly accelerated ischemia-induced shortening of
ARI (Fig. 1). Infusion of 5-HD did not modify the time
course of ARI after ischemia (Fig. 1A). In contrast,
HMR1098 blunted ischemia-induced ARI shortening and
abolished the effects of nicorandil on ARI change during
ischemia (Fig. 1B). Postischemic recovery of LVDP and
LVEDP were improved in the nicorandil-treated group
(Table 1). These beneficial effects of nicorandil were abol-
ished by 5-HD and HMR1098, though these KATP channel
blockers alone did not aggravate the postischemic contrac-
tile dysfunction.
INFARCT SIZE DATA. The volumes of myocardial infarct
size are summarized in Table 2. Nicorandil reduced in-
farct size as a percentage of the left ventricle (%IS/LV) from
53.2  4.1% in controls to 5.3  1.6% (p  0.05). Although
neither 5-HD nor HMR1098 alone changed infarct size,
5-HD completely abolished and HMR1098 significantly at-
tenuated the infarct size-limiting effect of nicorandil
(%IS/LV  53.0  6.3 and 21.3  5.0, respectively).
PROTOCOL 2. Hemodynamic parameters. In this protocol, 31
hearts were used, and one heart was excluded according to
the exclusion criteria. As shown in Table 3, no significant
effects of calphostin C and MPG pretreatment on heart
rate, LVDP, LVEDP, and coronary flow were detected.
Neither of these agents interfered with coronary dilation by
nicorandil. Nicorandil suppressed elevation of LVEDP after
ischemia/reperfusion regardless of pretreatment with cal-
phostin C and MPG.
INFARCT SIZE DATA. As shown in Table 4, an infarct
size-limiting effect of nicorandil was observed as in protocol
1, and neither calphostin C nor MPG abolished this
cardioprotection. Calphostin C and MPG alone did not
modify infarct size.
Experiment 2. Ischemic preconditioning (PC) induced
translocation of PKC- from the cytosol to the particulate
fraction (Fig. 2). However, significant translocation of
PKC- was not observed in hearts pretreated with calphos-
tin C. These results confirm that 200 nM calphostin C is
sufficient to inhibit PKC- in isolated rabbit hearts. In
contrast with PKC-, PKC- did not translocate to the
particulate fraction after PC (data not shown), as previously
reported for rabbit hearts by Ping et al. (28).
DISCUSSION
Contribution of sarcKATP and mitoKATP channels to
protection afforded by nicorandil. In the present study,
the infarct size-limiting effect of nicorandil was completely
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abolished by 5-HD but only partially inhibited by
HMR1098. The dose of HMR1098 was more than fourfold
higher than its reported IC50 for the sarcKATP channel
(18,19), and it was sufficient to inhibit both ischemia-
induced ARI shortening and its acceleration by nicorandil
(Fig. 1B). Therefore, it is highly unlikely that the dose of
HMR1098 was insufficient to block the sarcKATP channel
in the present preparation. In contrast with HMR1098,
Table 1. Summary of Hemodynamic Parameters in Protocol 1
Treatment n Baseline After Tx Reperfusion 30 Min Reperfusion 120 Min
Heart rate (beats/min)
Control 10 225  7 224  6 212  6 203  1
Nicorandil 7 222  6 219  6 209  7 206  4
5-HD 6 223  6 214  6 205  3 200  0
5-HD  nicorandil 6 220  9 215  6 207  4 204  3
HMR 6 229  9 223  9 206  2 205  2
HMR  nicorandil 5 218  5 215  5 200  0 200  0
LVDP (mm Hg)
Control 10 108  3 105  3 40  4 35  4
Nicorandil 7 113  8 110  9 85  5*† 79  6*†
5-HD 6 111  6 107  7 31  6 28  6
5-HD  nicorandil 6 109  7 107  6 35  5 29  4
HMR 6 102  4 96  4 38  6 28  5
HMR  nicorandil 5 100  7 100  7 47  8 50  6
LVEDP (mm Hg)
Control 10 0  0 0  0 29  4 24  3
Nicorandil 7 0  0 0  0 1  0*† 0  0*†
5-HD 6 0  0 0  0 38  4 30  3
5-HD  nicorandil 6 0  0 0  0 25  3 19  2
HMR 6 0  0 0  0 28  9 25  10
HMR  nicorandil 5 0  0 0  0 18  3 12  3
Coronary flow (ml/min)
Control 10 71  3 70  2 37  2 28  2
Nicorandil 7 72  3 98  3* 61  2* 47  3*
5-HD 6 68  2 67  2 41  4 33  5
5-HD  nicorandil 6 70  4 106  3* 40  5 38  4
HMR 6 71  4 64  5 36  3 29  3
HMR  nicorandil 5 65  3 103  3* 50  4 36  4
Mean  SE. *p  0.05 vs. control; †p  0.05 vs. 5-HD  nicorandil and HMR  nicorandil.
After Tx after treatment; HMRHMR1098; LVEDP left ventricular end-diastolic pressure; LVDP left ventricular
developed pressure; 5-HD  5-hydroxydecanoate.
Figure 1. Time course of the activation recovery interval (ARI) before and during ischemia. (A) ARIs in control (open circles), nicorandil (solid circles),
5-hydroxydecanoate (5-HD) (open triangles), and 5-HD  nicorandil (solid triangles) groups. (B) ARIs in HMR1098 (open squares) and HMR1098
 nicorandil (solid squares) groups. Open and solid circles are the same as those in A. *p  0.05 vs. control; #p  0.05 vs. nicorandil. Base  baseline;
Tx  drug treatment.
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5-HD at a dose of 100 M had no effect on shortening of
ARI during ischemia (Fig. 1), suggesting a lack of its effect
on the sarcKATP channel. Taken together, the present
results suggest that the mitoKATP channel plays a primary
role in infarct size limitation by nicorandil and that the
sarcKATP channel has a limited but significant contribution
to the cardioprotection.
Whether these two KATP channel subtypes share a
common effector or play distinctive roles in nicorandil-
induced protection is not clear. However, two speculations
can be made regarding the present results. First, activation
of the sarcKATP channel may facilitate opening of the
mitoKATP channel. Second, activation of the mitoKATP
channel may produce signals to the sarcKATP channel and
also to a sarcKATP channel-independent cardioprotective
mechanism. There is some evidence to argue for and against
either of these two possibilities. Hyperpolarization, which
sarcKATP channel opening would induce, has been shown to
activate phospholipase D (32), which could trigger a signal-
ing cascade to the mitoKATP channel (22,23). On the other
hand, mitoKATP channel opening triggers release of free
radicals (14,15,33) and possibly other signaling molecules
from the mitochondria (34,35), which could indirectly
modulate the sarcKATP channel and other cardioprotective
mechanisms. Nevertheless, it is notable that nicorandil is
not the only agent of which protective effects depend on
both the sarcKATP and mitoKATP channels. Actually, both
of these KATP channels have been shown to contribute to
cardioprotection afforded by PKC activation (19) and to
Table 2. Summary of Infarct Size Data in Protocol 1
Treatment n LV (cm3) Infarct (cm3) %IS/LV
Control 10 2.56  0.10 1.38  0.13 53.2  4.1
Nicorandil 7 2.49  0.15 0.13  0.04*† 5.3  1.6*†
5-HD 6 2.53  0.13 1.42  0.15 56.1  6.2
5-HD  nicorandil 6 2.40  0.13 1.30  0.20 53.0  6.3
HMR 6 2.36  0.11 1.16  0.08 49.7  4.1
HMR  nicorandil 5 2.35  0.14 0.52  0.14* 21.3  5.0*
Mean  SE. *p  0.05 vs. control; †p  0.05 vs. 5-HD  nicorandil and HMR 
nicorandil.
HMR  HMR1098; LV  left ventricle; 5-HD  5-hydroxydecanoate;
%IS/LV  infarct size as a percentage of left ventricle.
Table 3. Summary of Hemodynamic Parameters in Protocol 2
Treatment n Baseline After Tx Reperfusion 30 Min Reperfusion 120 Min
Heart rate (beats/min)
Control 5 221  9 225  8 218  10 209  1
Nicorandil 5 231  13 227  9 212  11 206  2
Cal C 5 215  2 201  5 200  0 200  0
Cal C  nicorandil 5 207  9 206  11 200  0 200  0
MPG 5 216  5 213  3 208  0 208  0
MPG  nicorandil 5 239  4 239  4 226  8 211  6
LVDP (mm Hg)
Control 5 115  6 120  6 38  3 39  6
Nicorandil 5 122  8 116  9 89  6* 72  6*
Cal C 5 106  10 102  10 33  3 31  4
Cal C  nicorandil 5 119  8 108  6 83  14* 62  12*
MPG 5 102  4 96  4 38  6 28  5
MPG  nicorandil 5 100  7 100  7 47  8 50  6
LVEDP (mm Hg)
Control 5 0  0 0  0 31  5 21  5
Nicorandil 5 0  0 0  0 2  1* 0  0*
Cal C 5 1  1 1  1 35  10 39  9
Cal C  nicorandil 5 2  1 1  1 1  1* 0  0*
MPG 5 0  0 0  0 28  9 25  10
MPG  nicorandil 5 0  0 0  0 8  3* 2  3*
Coronary flow (ml/min)
Control 5 62  6 63  6 39  6 29  5
Nicorandil 5 73  4 94  5* 68  2* 49  5*
Cal C 5 67  5 66  4 38  5 26  3
Cal C  nicorandil 5 66  6 100  4* 54  2* 36  2
MPG 5 71  4 64  5 36  3 29  3
MPG  nicorandil 5 65  3 103  3* 50  4 36  4
Mean  SE. *p  0.05 vs. control.
After Tx  after treatment; Cal C  calphostin C; LVEDP  left ventricular end-diastolic pressure; LVDP  left
ventricular developed pressure; MPG  N-2-mercaptopropionylglycine.
Table 4. Summary of Infarct Size Data in Protocol 2
Treatment n LV (cm3) Infarct (cm3) %IS/LV
Control 5 2.42  0.18 1.13  0.13 46.9  4.8
Nicorandil 5 2.15  0.07 0.13  0.05* 6.0  2.5*
Cal C 5 2.11  0.30 1.27  0.13 50.5  6.8
Cal C  nicorandil 5 2.17  0.34 0.10  0.07* 6.4  3.3*
MPG 5 2.56  0.07 1.26  0.21 48.6  7.3
MPG  nicorandil 5 2.15  0.07 0.23  0.08* 10.3  3.5*
Mean  SE. *p  0.05 vs. control.
Cal C  calphostin C; LV  left ventricle; MPG  N-2-mercaptopropionylglycine.
%IS/LV  infarct size as a percentage of left ventricle.
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protection by preconditioning in some experimental prepa-
rations (36,37).
PKC and cardioprotective effects of nicorandil. Nicoran-
dil is an NO donor, though its NO-releasing mechanism is
independent of glutathione-S-transferase unlike that in
organic nitrates (20,21). There is recent evidence supporting
the notion that NO protects the ischemic myocardium by
PKC-mediated mechanisms. Ping et al. (28) demonstrated
that PKC- and PKC- were activated by two structurally
different NO donors (i.e., SNAP and dimethylenetriamine/
NO) in rabbit hearts. A study by Nakano et al. (13) has
shown that infarct size-limiting effect of SNAP was abol-
ished by a PKC inhibitor, chelerythrine, and by MPG,
suggesting that both PKC and free radicals are involved in
NO-induced anti-infarct tolerance. Furthermore, produc-
tion of free radicals by nicorandil administration in the heart
was suggested in a recent study using formation of 2,3-
dihydroxybenzoic acid as an index of hydroxyl free radical
production (33). Because free radicals are activators of PKC,
these findings are consistent with the recent hypothesis that
nitrate-derived oxyradicals trigger PKC-mediated cardio-
protection against infarction (28,38).
However, such a PKC-mediated mechanism is unlikely
to be important in infarct size limitation by nicorandil. In
contrast with the reported cardioprotection by SNAP, the
infarct size-limiting effect of nicorandil was not eliminated
by calphostin C or by MPG (Table 4). The dose of
calphostin C was fourfold higher than its IC50 to inhibit
PKC activity (i.e., 50 M). Furthermore, this dose was
sufficient to prevent PKC translocation by preconditioning
(Fig. 2) and to abolish cardioprotective signaling from
activated adenosine receptors (25). The MPG dose used in
the present study has been confirmed by our previous study
(39) to be sufficient for abolishing the free radical-induced
trigger mechanism of preconditioning. Taken together, the
results suggest that, even if NO-mediated PKC activation
contributes to opening of mitoKATP channel by nicorandil,
such a PKC activation is unlikely to be crucial, and direct
activation of the mitoKATP channel by this agent is of
primary importance in the anti-infarct tolerance.
The role of PKC in cardioprotection by KATP channel
openers has been examined for diazoxide, a mitoKATP
channel-selective opener, which lacks nitrate property. Our
previous study (25) and a study by Pain et al. (14) have
shown that PKC inhibitors (calphostin C and cheleryhrine)
did not abolish infarct size-limiting effect of diazoxide in
rabbit hearts. In contrast, the same PKC inhibitors report-
edly eliminated the protective effects of diazoxide against
ischemia/reperfusion injury in buffer-perfused rat hearts
(40). This discrepancy cannot be clearly explained but may
reflect species differences in regulatory mechanisms of PKC
and the mitoKATP channel.
Activation of the mitoKATP and sarcKATP channels by
nicorandil. Although a number of investigators have been
interested in the mitoKATP channel in cardiomyocytes, the
molecular structure of this channel has not yet been char-
acterized. In isolated cardiomyocytes neither a dominant-
negative construct of Kir6.1 nor that of Kir6.2 affected
mitoKATP channel activity (41). Regarding the sulfonylurea
receptor (SUR) subtype in the mitoKATP channel, Liu et al.
(42) recently showed that responses of this channel to KATP
channel openers (diazoxide, pinacidil) and blockers (gliben-
clamide, 5-HD, HMR1098) resembled those of a SUR1/
Kir6.1 complex expressed in HEK293 cells. It is notable
that nicorandil did not activate the pancreatic -cell KATP
channels consisting of SUR1/Kir6.1 complex (43) but
afforded cardioprotection against infarction. Furthermore,
this protective effect was inhibitable by 5-HD (Table 2) as
was diazoxide-induced protection (25). These findings sug-
gest that nicorandil binds to a specific site of SUR in the
mitoKATP channel, which is not commonly present in the
SUR1.
Figure 2. Effects of calphostin C on translocations of protein kinase C (PKC)- by ischemic preconditioning (PC). The PKC- levels in the cytosol and
particulate fraction are expressed as percentages of the total. Ischemic preconditioning significantly reduced PKC- in the cycotol and increased PKC in
the particulate fraction, indicating translocation of PKC- from the cytosol to the particulate fraction. In the hearts pretreated with calphostin C (200 nM),
translocation of PKC- was not detected. Open bar  cytosol; hatched bar  particulate. *p  0.05 vs. baseline. n  4 in each treatment group.
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Recently, Sato et al. (44) showed that up to 1 mM
nicorandil failed to open the sarcKATP channel, though the
mitoKATP channel was activated by 100 M of nicorandil
in isolated rabbit cardiomyocytes. These features of nicoran-
dil are very similar to those of diazoxide, a “mitoKATP
channel-selective” opener. The observation by Sato et al.
(44) is actually consistent with our finding that nicorandil
did not modify ARI before ischemia. Activation of the
sarcKATP channel by nicorandil, which is indicated by
accelerated ARI shortening, after the onset of ischemia is
presumably due to enhanced sensitivity of the sarcKATP
channel to a KATP channel opener by accumulation of
cytosolic adenosine diphosphate (45).
Conclusions. This study indicates that both the sarcKATP
and mitoKATP channels contribute to anti-infarct tolerance
afforded by nicorandil and that PKC activation induced by
NO or oxygen-free radical generation, if any, does not play
a crucial role. Whether these two KATP channel subtypes
link to a common effector or play distinctive roles in
nicorandil-induced protection warrants further investiga-
tion.
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